Literature DB >> 27550453

WWOX and p53 Dysregulation Synergize to Drive the Development of Osteosarcoma.

Sara Del Mare1, Hussam Husanie1, Ortal Iancu1, Mohammad Abu-Odeh1, Konstantinos Evangelou2, Francesca Lovat3, Stefano Volinia4, Jonathan Gordon5, Gail Amir6, Janet Stein5, Gary S Stein5, Carlo M Croce3, Vassilis Gorgoulis7, Jane B Lian4, Rami I Aqeilan8.   

Abstract

Osteosarcoma is a highly metastatic form of bone cancer in adolescents and young adults that is resistant to existing treatments. Development of an effective therapy has been hindered by very limited understanding of the mechanisms of osteosarcomagenesis. Here, we used genetically engineered mice to investigate the effects of deleting the tumor suppressor Wwox selectively in either osteoblast progenitors or mature osteoblasts. Mice with conditional deletion of Wwox in preosteoblasts (WwoxΔosx1) displayed a severe inhibition of osteogenesis accompanied by p53 upregulation, effects that were not observed in mice lacking Wwox in mature osteoblasts. Deletion of p53 in WwoxΔosx1 mice rescued the osteogenic defect. In addition, the Wwox;p53Δosx1 double knockout mice developed poorly differentiated osteosarcomas that resemble human osteosarcoma in histology, location, metastatic behavior, and gene expression. Strikingly, the development of osteosarcomas in these mice was greatly accelerated compared with mice lacking p53 only. In contrast, combined WWOX and p53 inactivation in mature osteoblasts did not accelerate osteosarcomagenesis compared with p53 inactivation alone. These findings provide evidence that a WWOX-p53 network regulates normal bone formation and that disruption of this network in osteoprogenitors results in accelerated osteosarcoma. The Wwox;p53Δosx1 double knockout establishes a new osteosarcoma model with significant advancement over existing models. Cancer Res; 76(20); 6107-17. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27550453      PMCID: PMC5146760          DOI: 10.1158/0008-5472.CAN-16-0621

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  39 in total

1.  Frequent attenuation of the WWOX tumor suppressor in osteosarcoma is associated with increased tumorigenicity and aberrant RUNX2 expression.

Authors:  Kyle C Kurek; Sara Del Mare; Zaidoun Salah; Suhaib Abdeen; Hussain Sadiq; Suk-Hee Lee; Eugenio Gaudio; Nicola Zanesi; Kevin B Jones; Barry DeYoung; Gail Amir; Mark Gebhardt; Matthew Warman; Gary S Stein; Janet L Stein; Jane B Lian; Rami I Aqeilan
Journal:  Cancer Res       Date:  2010-06-08       Impact factor: 12.701

2.  Distinct roles for Hedgehog and canonical Wnt signaling in specification, differentiation and maintenance of osteoblast progenitors.

Authors:  Stephen J Rodda; Andrew P McMahon
Journal:  Development       Date:  2006-07-19       Impact factor: 6.868

3.  Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer.

Authors:  J Jonkers; R Meuwissen; H van der Gulden; H Peterse; M van der Valk; A Berns
Journal:  Nat Genet       Date:  2001-12       Impact factor: 38.330

4.  Genomic promoter occupancy of runt-related transcription factor RUNX2 in Osteosarcoma cells identifies genes involved in cell adhesion and motility.

Authors:  Margaretha van der Deen; Jacqueline Akech; David Lapointe; Sneha Gupta; Daniel W Young; Martin A Montecino; Mario Galindo; Jane B Lian; Janet L Stein; Gary S Stein; Andre J van Wijnen
Journal:  J Biol Chem       Date:  2011-12-09       Impact factor: 5.157

5.  WWOX: a candidate tumor suppressor gene involved in multiple tumor types.

Authors:  A J Paige; K J Taylor; C Taylor; S G Hillier; S Farrington; D Scott; D J Porteous; J F Smyth; H Gabra; J E Watson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-25       Impact factor: 11.205

6.  Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma.

Authors:  Jennifer A Perry; Adam Kiezun; Peter Tonzi; Eliezer M Van Allen; Scott L Carter; Sylvan C Baca; Glenn S Cowley; Ami S Bhatt; Esther Rheinbay; Chandra Sekhar Pedamallu; Elena Helman; Amaro Taylor-Weiner; Aaron McKenna; David S DeLuca; Michael S Lawrence; Lauren Ambrogio; Carrie Sougnez; Andrey Sivachenko; Loren D Walensky; Nikhil Wagle; Jaume Mora; Carmen de Torres; Cinzia Lavarino; Simone Dos Santos Aguiar; Jose Andres Yunes; Silvia Regina Brandalise; Gabriela Elisa Mercado-Celis; Jorge Melendez-Zajgla; Rocío Cárdenas-Cardós; Liliana Velasco-Hidalgo; Charles W M Roberts; Levi A Garraway; Carlos Rodriguez-Galindo; Stacey B Gabriel; Eric S Lander; Todd R Golub; Stuart H Orkin; Gad Getz; Katherine A Janeway
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-15       Impact factor: 11.205

7.  miRNA signatures associate with pathogenesis and progression of osteosarcoma.

Authors:  Kevin B Jones; Zaidoun Salah; Sara Del Mare; Marco Galasso; Eugenio Gaudio; Gerard J Nuovo; Francesca Lovat; Kimberly LeBlanc; Jeff Palatini; R Lor Randall; Stefano Volinia; Gary S Stein; Carlo M Croce; Jane B Lian; Rami I Aqeilan
Journal:  Cancer Res       Date:  2012-02-20       Impact factor: 12.701

8.  The impact of osteoblastic differentiation on osteosarcomagenesis in the mouse.

Authors:  T Quist; H Jin; J-F Zhu; K Smith-Fry; M R Capecchi; K B Jones
Journal:  Oncogene       Date:  2014-10-27       Impact factor: 9.867

9.  Tumor suppressor WWOX binds to ΔNp63α and sensitizes cancer cells to chemotherapy.

Authors:  Z Salah; T Bar-mag; Y Kohn; F Pichiorri; T Palumbo; G Melino; R I Aqeilan
Journal:  Cell Death Dis       Date:  2013-01-31       Impact factor: 8.469

10.  Osteoblast differentiation and skeletal development are regulated by Mdm2-p53 signaling.

Authors:  Christopher J Lengner; Heather A Steinman; James Gagnon; Thomas W Smith; Janet E Henderson; Barbara E Kream; Gary S Stein; Jane B Lian; Stephen N Jones
Journal:  J Cell Biol       Date:  2006-03-13       Impact factor: 10.539

View more
  21 in total

Review 1.  Phosphorylation/de-phosphorylation in specific sites of tumor suppressor WWOX and control of distinct biological events.

Authors:  Shenq-Shyang Huang; Nan-Shan Chang
Journal:  Exp Biol Med (Maywood)       Date:  2018-01-08

2.  Association between genetic variants in p53 binding sites and risks of osteosarcoma in a Chinese population: a two-stage case-control study.

Authors:  Jingzhe Zhang; Li Kai; Wenlong Zhang; Yu Yin; Wenjun Wang
Journal:  Cancer Biol Ther       Date:  2018-06-18       Impact factor: 4.742

Review 3.  Decoding the link between WWOX and p53 in aggressive breast cancer.

Authors:  Suhaib K Abdeen; Rami I Aqeilan
Journal:  Cell Cycle       Date:  2019-05-16       Impact factor: 4.534

Review 4.  Molecular Functions of WWOX Potentially Involved in Cancer Development.

Authors:  Karim Taouis; Keltouma Driouch; Rosette Lidereau; François Lallemand
Journal:  Cells       Date:  2021-04-29       Impact factor: 6.600

5.  Genome-wide high-resolution mapping of mitotic DNA synthesis sites and common fragile sites by direct sequencing.

Authors:  Fang Ji; Hongwei Liao; Sheng Pan; Liujian Ouyang; Fang Jia; Zaiyang Fu; Fengjiao Zhang; Xinwei Geng; Xinming Wang; Tingting Li; Shuangying Liu; Madiha Zahra Syeda; Haixia Chen; Wen Li; Zhihua Chen; Huahao Shen; Songmin Ying
Journal:  Cell Res       Date:  2020-06-19       Impact factor: 46.297

Review 6.  HYAL-2-WWOX-SMAD4 Signaling in Cell Death and Anticancer Response.

Authors:  Li-Jin Hsu; Ming-Fu Chiang; Chun-I Sze; Wan-Pei Su; Ye Vone Yap; I-Ting Lee; Hsiang-Ling Kuo; Nan-Shan Chang
Journal:  Front Cell Dev Biol       Date:  2016-12-06

Review 7.  Functions and Epigenetic Regulation of Wwox in Bone Metastasis from Breast Carcinoma: Comparison with Primary Tumors.

Authors:  Paola Maroni; Emanuela Matteucci; Paola Bendinelli; Maria Alfonsina Desiderio
Journal:  Int J Mol Sci       Date:  2017-01-01       Impact factor: 5.923

8.  Hyaluronan activates Hyal-2/WWOX/Smad4 signaling and causes bubbling cell death when the signaling complex is overexpressed.

Authors:  Li-Jin Hsu; Qunying Hong; Shur-Tzu Chen; Hsiang-Lin Kuo; Lori Schultz; John Heath; Sing-Ru Lin; Ming-Hui Lee; Dong-Zhang Li; Zih-Ling Li; Hui-Ching Cheng; Gerard Armand; Nan-Shan Chang
Journal:  Oncotarget       Date:  2017-03-21

9.  In Vitro Screening for Cytotoxic Activity of Herbal Extracts.

Authors:  Valter R M Lombardi; Iván Carrera; Ramón Cacabelos
Journal:  Evid Based Complement Alternat Med       Date:  2017-03-13       Impact factor: 2.629

Review 10.  Modeling WWOX Loss of Function in vivo: What Have We Learned?

Authors:  Mayur Tanna; Rami I Aqeilan
Journal:  Front Oncol       Date:  2018-10-10       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.